<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615718</url>
  </required_header>
  <id_info>
    <org_study_id>2012-p-001120</org_study_id>
    <secondary_id>1R44NS080632</secondary_id>
    <nct_id>NCT01615718</nct_id>
  </id_info>
  <brief_title>Non-invasive Neurostimulation in Parkinson's Disease</brief_title>
  <official_title>Effects of Non-invasive Neurostimulation Methods on Motor Function in Parkinson's Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spaulding Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Highland Instruments, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spaulding Rehabilitation Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to investigate the effects of non-invasive
      neurostimulation - low-intensity transcranial electrical stimulation in conjunction with
      transcranial ultrasound (TUS)- on the motor symptoms associated with Parkinson's disease. The
      investigators want to see if there is a difference between active and sham stimulation on
      these motor symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Motor Function</measure>
    <time_frame>Measured for approximately 2 months</time_frame>
    <description>We will measure motor symptoms using the Unified Parkinson's Disease Rating Scale (UPDRS), bradykinesia tests and walking tests. We will assess the changes in these scales from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Measured for approximately 2 months</time_frame>
    <description>We will measure safety using a battery of electrophysiology, cognitive and neurological safety markers. We will use the Scales for Outcomes in PD-Cognitive (SCOPA-COg), the n-back working memory test, adverse effects questionnaire, electroencephalography (EEG) and a standardized neurological exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological Changes</measure>
    <time_frame>Measured for approximately 2 months</time_frame>
    <description>We will also use transcranial magnetic stimulation (TMS) and Doppler Ultrasound to assess electrophysiology and cerebral bloodflow markers.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Active Electrical Stim/Active Ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Electrical Stim/Sham Ultrasound</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Electrical Stim/Sham Ultrasound</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Electrical Stim/Active Ultrasound</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>low-intensity transcranial electrical stimulation</intervention_name>
    <description>Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.</description>
    <arm_group_label>Active Electrical Stim/Active Ultrasound</arm_group_label>
    <arm_group_label>Sham Electrical Stim/Sham Ultrasound</arm_group_label>
    <arm_group_label>Active Electrical Stim/Sham Ultrasound</arm_group_label>
    <arm_group_label>Sham Electrical Stim/Active Ultrasound</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcranial ultrasound</intervention_name>
    <description>Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.</description>
    <arm_group_label>Active Electrical Stim/Active Ultrasound</arm_group_label>
    <arm_group_label>Sham Electrical Stim/Sham Ultrasound</arm_group_label>
    <arm_group_label>Active Electrical Stim/Sham Ultrasound</arm_group_label>
    <arm_group_label>Sham Electrical Stim/Active Ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of PD diagnosis from their clinician by either a letter or verification
             through their medical record

          -  Research criteria of &quot;possible&quot; or &quot;probable&quot; PD, as defined by Gelb et al (Gelb D,
             Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. Arch
             Neurol.1999;56:33-39)[1]

          -  Age 40 or over;

          -  Taking stable medications for at least 30 days

        Exclusion Criteria:

          -  Features suggestive of other causes of parkinsonism/Parkinson's-plus syndromes;

          -  History of deep brain stimulation or ablation surgery, mass brain lesions;

          -  History of schizophrenia, schizoaffective disorder, other psychosis, episode of
             bipolar illness, alcohol/drug abuse within the past year;

          -  Need for rapid clinical response due to conditions such as initiation, psychosis, or
             suicidal;

          -  Contraindications to transcranial brain stimulation or TUS, i.e. metal in the head,
             implanted brain medical devices, etc;

          -  Unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues,
             heart failure, pulmonary issues, or chronic obstructive pulmonary disease);

          -  Pregnancy.

          -  Epilepsy or disorders that increase likelihood of seizures including: moderate or
             severe traumatic brain injury, congenital birth defects leading to seizures, brain
             tumor, metabolism disorders associated with seizures, and nonlacunar stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Wagner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Highland Instruments, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Fregni, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe Fregni, MD, PhD, MPH</last_name>
    <phone>617-952-6156</phone>
    <email>ffregni@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie French, BS</last_name>
    <phone>617-952-6151</phone>
    <email>mnfrench@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spaulding Rehabilitation Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spaulding Rehabilitation Hospital</investigator_affiliation>
    <investigator_full_name>Felipe Fregni</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>noninvasive stimulation</keyword>
  <keyword>motor function</keyword>
  <keyword>transcranial stimulation</keyword>
  <keyword>transcranial ultrasound</keyword>
  <keyword>brain stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

